Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 234

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 234
---
10.77 As of June 30, 2025, there was approximately $8.3 million of unrecognized stock-based compensation expense related to RSU awards that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.64 years. Stock OptionsA summary of option activity during the six months ended June 30, 2025 is as follows (in thousands except share and per share data):NUMBER OF OPTIONSWEIGHTED-AVERAGE EXERCISE PRICEOutstanding as of December 31, 20245,384,760 $42.19 Granted84,000 14.82 Exercised(60,709)0.34 Cancelled or Forfeited (143,117)53.31 Expired(14,674)$47.90 Outstanding as of June 30, 20255,250,260 $41.92 Options exercisable as of June 30, 20253,465,140 $36.70 The summary of option activity includes performance-based stock options granted during 2024. As of June 30, 2025, there has been no expense recognized for the performance-based stock options. The weighted-average grant date fair value price 

13

per share of options granted during the six months ended June 30, 2025 and 2024 was $10.36 and $40.62, respectively. As of June 30, 2025, there was $61.2 million of unrecognized stock-based compensation expense related to unvested stock options, including $4.9 million of unrecognized stock-based compensation expense related to unvested performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 2.03 years. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of the stock options outstanding and stock options exercisable was $5.4 million and $5.4 million as of June 30, 2025, respectively. The aggregate intrinsic value of stock options exercised was $0.6 million and $7.3 million during the six months ended June 30, 2025 and 2024, respectively. 2020 Employee Stock Purchase Plan In March 2020